Spero Therapeutics

📍 Cambridge, United States🗓 Founded 2013👥 62 employees💰 Last funded Apr 2014

Biotechnology Research 🌐 sperotherapeutics.com

We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases. Spero’s lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Spero’s partnership directed programs consist of SPR206 and tebipenem HBr, which through the company’s business development efforts, have joint venture relationships supporting their ongoing development. SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections, in the hospital setting. Tebipenem HBr, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections, or cUTIs, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. We believe that our novel product candidates will have a meaningful impact on patient health and significant commercial applications for treating MDR infections in hospitals and community settings.

Total investors

Early stage

Mid stage

Late stage

2013

Founded